Imvax Advances a New Approach to Personalized Cancer Immunotherapy
**Sponsored Content**
Learn more about Imvax’s Phase 2b trial studying a personalized, whole tumor-derived immunotherapy in newly diagnosed patients with glioblastoma.
Sign up for our bi-monthly email to get the latest news on treatments, support, and stories from the brain tumor community.
